Unit of General Pathology and Immunology, Department of Biomedical Sciences and Biotechnology, School of Medicine, University of Brescia, Brescia, 25123, Italy; E-Mails:
Sensors (Basel). 2009;9(8):6471-503. doi: 10.3390/s90806471. Epub 2009 Aug 20.
Angiogenesis, the process of new blood vessel formation, is implicated in various physiological/pathological conditions, including embryonic development, inflammation and tumor growth. Fibroblast growth factor-2 (FGF2) is a heparin-binding angiogenic growth factor involved in various physiopathological processes, including tumor neovascularization. Accordingly, FGF2 is considered a target for antiangiogenic therapies. Thus, numerous natural/synthetic compounds have been tested for their capacity to bind and sequester FGF2 in the extracellular environment preventing its interaction with cellular receptors. We have exploited surface plasmon resonance (SPR) technique in search for antiangiogenic FGF2 binders/antagonists. In this review we will summarize our experience in SPR-based angiogenesis research, with the aim to validate SPR as a first line screening for the identification of antiangiogenic compounds.
血管生成，即新血管形成的过程，与多种生理/病理状况有关，包括胚胎发育、炎症和肿瘤生长。成纤维细胞生长因子 2（FGF2）是一种肝素结合的血管生成生长因子，参与多种生理病理过程，包括肿瘤新生血管形成。因此，FGF2 被认为是抗血管生成治疗的靶点。因此，已经测试了许多天然/合成化合物，以检测它们在细胞外环境中结合和隔离 FGF2 的能力，从而阻止其与细胞受体相互作用。我们利用表面等离子体共振（SPR）技术寻找抗血管生成 FGF2 结合物/拮抗剂。在这篇综述中，我们将总结我们在基于 SPR 的血管生成研究方面的经验，目的是验证 SPR 作为识别抗血管生成化合物的一线筛选方法。
